MitoSense, Inc.

06/02/2026

This Lou Gehrig Day, MitoSense honors the legacy and courage of the baseball great.

And we are honored to be officially working with the U.S. Department of Veterans Affairs to develop a treatment for .

This is a fight we must win.

lou Gherig speaks on July 4th about his ALS disease

05/26/2026

reminds us why innovation matters. Every breakthrough starts with a belief that better treatments are possible.

MitoSense is proud to support the fight for progress, hope, and meaningful impact through mitochondrial science.

04/23/2026

"And it may just be the biggest medical breakthrough you've never heard of until now."

— Dr. Robert Lufkin, M.D. on
Organelle Transplantation

Why are more physicians paying attention to mitochondrial medicine?

Watch the full conversation:

What if aging, ALS, Parkinson's, stroke, and diabetes all share a single upstream cause — and the fix is a transplant the size of a bacterium? Dr. Catherine ...

04/10/2026

04/01/2026

Most promising: transferred healthy mitochondria boosted ATP production by ~70% in patient cells.

This supports organelle transplantation (MOT) as a real therapeutic pathway—not theory, but measurable rescue. The future of mitochondrial medicine is getting closer! https://www.sciencedirect.com/science/article/pii/S2214426926000145?ref=pdf_download&fr=RR-2&rr=9e578de10ab7d65d

03/28/2026

Dr. Robert Lufkin MD is a national treasure. This will be a must watch!

03/05/2026

Federal support of $1.1 million to Greenwood Genetic Center will drive progress in the Carroll A. Campbell Jr. Alzheimer's Initiative.

Excited for the role our MOT™ technology plays in this collaborative effort to develop new treatments for Alzheimer's disease.

MitoSense Inc. congratulates its partner, Greenwood Genetic Center (GGC), on receiving $1,106,000 in new federal funding to advance Alzheimer’s disease research and on the publication of a new peer reviewed genetic study from the same Alzheimer’s Initiative team demonstrating the impact of mitoc...

03/05/2026

Could transfers of healthy power sources into cells lead to therapies for treating diseases of the central nervous system, where cells stop working or die?

02/25/2026

The Greenwood Genetic Center (GGC) has received $1,106,000 in Congressionally Directed Spending through the U.S. Department of Health and Human Services to support advanced research equipment for the Carroll A. Campbell Jr. Alzheimer’s Initiative. This collaborative effort between GGC, MitoSense, ...

02/11/2026

Groundbreaking paper in Alzheimer's & Dementia reveals mitochondrial dysfunction as a core driver in neurodegeneration.

Targeting mito health could unlock new therapies for Alzheimer's & beyond. Essential read for advancing brain disease treatments!

Background Mitochondrial DNA copy number (mtDNAcn) quantifies the number of mitochondria genomes per nucleated cell, with lower mtDNAcn linked to increased Alzheimer’s disease (AD) and Parkinson’s d...